Table S1: Inclusion and Exclusion Criteria for PHYOX1-Group A Participants

Inclusion Criteria

Healthy volunteers must have met all of the following criteria to be eligible for participation in this study.

1. Participant understood the full nature and purpose of the study, including possible risks and side effects, and was willing and able to comply with all study procedures and restrictions.
2. Male or female participants between 18 and 55 years of age, inclusive
3. Participant must have had a BMI 19.0 to 32.0 kg/m^2, inclusive.
4. Non-smokers, at least 1-month tobacco free, and willing to remain tobacco free through end of study (EOS). Participants must also have been free from nicotine-containing products (e.g., nicotine patch).
5. Participant must have been otherwise healthy. Healthy status was defined based on the opinion of the principal investigator.
6. Participants must have had hematology and clinical chemistry tests and urine analyses within the normal range.
7. Female and male participants, as well as female partner(s) of male participants who were of childbearing potential, must have been willing to use a highly effective and approved contraceptive method (s) from the date of informed consent until 12 weeks after the last dose of investigational medical product (IMP).
8. Postmenopausal females: defined as 12 months with no menses prior to Screening without an alternative medical cause and a serum FSH in the menopausal range at screening visit.
9. For female participants: a negative pregnancy test at Screening and Day 0 visit.

Exclusion Criteria

Healthy volunteers meeting any of the following criteria were to be excluded from this study:

1. Presence of any medical condition or co-morbidities that would interfere with study compliance or data interpretation or potentially impact participant safety including, but not restricted to:
    a. Severe intercurrent illness
    b. Routine vaccination within 30 days prior to dosing and through EOS visit
    c. Known causes of active liver disease/injury or transaminase elevation (e.g., alcoholic liver disease, nonalcoholic fatty liver disease/nonalcoholic steatohepatitis)
    d. Physician concerns about excess alcohol consumption
    e. Routine or chronic use of more than 3 grams of paracetamol daily

   f. Any clinically significant (in the opinion of the investigator), age-appropriate abnormality in screening data (including serum chemistry, hematology, coagulation parameters, blood pressure, pulse rate, and ECG findings)

2. History of kidney stones
3. Women who were pregnant, lactating, or planned to attempt to become pregnant during this study or within 90 days after last dosing of IMP
4. Male participants with female partners who were planning to attempt to become pregnant during this study or within 90 days after last dosing of IMP
5. Use of any investigational agent within 90 days before the first dose of study medication. If a participant participated in prior siRNA or antibody studies, a washout period of at least 6 months before the first administered dose in this study was required.
6. Strenuous activity, sunbathing, and contact sports within 48 hours (2 days) prior to dose administration and through to the EOS visit or Day 29
7. History of donation of more than 450 mL of blood within 90 days prior to dosing in the clinical research center or planned donation less than 30 days after receiving IMP
8. Plasma or platelet donation within 7 days of dosing and throughout the entire study
9. History of alcohol consumption exceeding 21 units in male participants, 14 units in female participants, per week as determined by the Investigator. Alcohol consumption was prohibited 48 hours prior to admission to the clinical facility and until the end of study.
10. Positive screening test for hepatitis B surface antigen, anti-hepatitis C virus antibodies, or anti-human immunodeficiency virus 1 and 2 antibodies
11. History of one or more of the following reactions to an oligonucleotide-based therapy:
    a. Severe thrombocytopenia
    b. Hepatotoxicity
    c. Severe flu-like symptoms leading to discontinuation of therapy
    d. Localized skin reaction from the injection (Grade 3 or higher) leading to discontinuation of therapy
    e. Coagulopathy/clinically important prolongation of clotting time
12. Known hypersensitivity to nedosiran or any of its ingredients